bioAffinity Technologies/$BIAF
1D1W1MYTD1Y5YMAX
Capital at risk
About bioAffinity Technologies
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
- Ticker
- $BIAF
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 57
- Headquarters
- San Antonio, United States
- Website
- bioaffinitytech.com
BIAF Metrics
BasicAdvanced
$4.7M
-
-$59.70
-1.05
-
Price and volume
Market cap
$4.7M
Beta
-1.05
52-week high
$109.35
52-week low
$4.56
Average daily volume
6.2M
Financial strength
Current ratio
1.442
Quick ratio
1.24
Long term debt to equity
0.31
Total debt to equity
0.381
Interest coverage (TTM)
-276.15%
Profitability
EBITDA (TTM)
-11.969
Gross margin (TTM)
34.61%
Net profit margin (TTM)
-257.33%
Operating margin (TTM)
-209.82%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-125.11%
Return on equity (TTM)
-1,860.15%
Valuation
Price to revenue (TTM)
0.377
Price to book
1.05
Price to tangible book (TTM)
2.36
Price to free cash flow (TTM)
-0.193
Free cash flow yield (TTM)
-519.37%
Free cash flow per share (TTM)
-45.445
Growth
Revenue change (TTM)
-23.17%
Earnings per share change (TTM)
-80.85%
3-year revenue growth (CAGR)
525.12%
3-year earnings per share growth (CAGR)
-53.68%
Upcoming events
No upcoming events
BIAF News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.